LENZ Therapeutics, Inc. - Common Stock (LENZ) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2024 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
LENZ on Nasdaq
Shares outstanding
31,382,102
Price per share
$16.00
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
29,140,610
Total reported value
$1,355,578,952
% of total 13F portfolios
0.01%
Share change
+4,411,883
Value change
+$224,910,234
Number of holders
166
Price from insider filings
$16.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LENZ Therapeutics, Inc. - Common Stock (LENZ) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% $199,280,597 4,278,244 FMR LLC 31 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 14% -10% $198,668,637 +$209,610 4,265,106 +0.11% RA Capital Management, L.P. 05 Nov 2025
BlackRock, Inc. 4.9% -4% $24,603,568 +$1,517,744 1,537,723 +6.6% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.8% $63,244,042 1,357,751 Steven A. Cohen 30 Sep 2025
Paradigm Biocapital Advisors LP 3.8% -28% $50,001,813 -$16,133,961 1,073,461 -24% Paradigm BioCapital Advisors LP 30 Sep 2025
Versant Venture Capital VI, L.P. 3.4% -18% $48,936,901 -$6,192,532 1,050,599 -11% Versant Venture Capital VI, L.P. 05 Nov 2025

As of 30 Sep 2025, 166 institutional investors reported holding 29,140,610 shares of LENZ Therapeutics, Inc. - Common Stock (LENZ). This represents 93% of the company’s total 31,382,102 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LENZ Therapeutics, Inc. - Common Stock (LENZ) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 13% 4,178,823 0% 2.4% $194,649,575
Alpha Wave Global, LP 12% 3,612,211 0% 17% $168,256,788
Versant Venture Management, LLC 8.5% 2,656,888 58% $123,757,843
BlackRock, Inc. 4.7% 1,473,104 +2.8% 0% $68,617,185
VANGUARD GROUP INC 4.2% 1,330,286 +3% 0% $61,964,723
UBS Group AG 3.8% 1,201,616 +36% 0.01% $55,971,274
Paradigm Biocapital Advisors LP 3.4% 1,073,461 -37% 1.5% $50,001,813
72 Investment Holdings, LLC 3.2% 1,017,751 0% 70% $47,406,842
TANG CAPITAL MANAGEMENT LLC 2.9% 897,616 0% 1.6% $41,810,953
RTW INVESTMENTS, LP 2.8% 863,389 0% 0.5% $40,216,660
First Light Asset Management, LLC 2.2% 693,044 3% $32,281,990
ADAGE CAPITAL PARTNERS GP, L.L.C. 2% 627,618 -44% 0.05% $29,234,446
FRANKLIN RESOURCES INC 1.9% 587,084 +6756% 0.01% $27,346,372
GEODE CAPITAL MANAGEMENT, LLC 1.4% 454,896 +9.3% 0% $21,193,422
STATE STREET CORP 1.3% 417,984 +11% 0% $19,469,695
CITADEL ADVISORS LLC 1.3% 399,430 +4320% 0.01% $18,605,449
Saturn V Capital Management LP 1.2% 368,176 +7.6% 3.8% $17,149,638
Invesco Ltd. 1.2% 364,265 +37% 0% $16,967,463
BANK OF AMERICA CORP /DE/ 1.1% 349,128 +414% 0% $16,262,383
SAMSARA BIOCAPITAL, LLC 1.1% 343,012 0% 2.1% $15,977,499
Point72 Asset Management, L.P. 1.1% 340,000 -45% 0.03% $15,837,200
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 1% 323,857 +35% 0.49% $15,085,259
MORGAN STANLEY 0.94% 296,219 -49% 0% $13,797,880
Nuveen, LLC 0.91% 285,543 +60% 0% $13,300,593
PRICE T ROWE ASSOCIATES INC /MD/ 0.8% 251,131 +1582% 0% $11,699,000

Institutional Holders of LENZ Therapeutics, Inc. - Common Stock (LENZ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 775,366 $12,819,564 +$6,467,470 $16.00 11
2025 Q3 29,140,610 $1,355,578,952 +$224,910,234 $46.58 166
2025 Q2 24,727,156 $725,109,733 +$107,969,187 $29.31 113
2025 Q1 21,072,237 $541,761,121 +$29,092,976 $25.71 105
2024 Q4 19,863,850 $573,239,116 +$35,341,897 $28.87 94
2024 Q3 18,735,645 $444,795,067 -$1,423,016 $23.74 78
2024 Q2 18,913,542 $327,016,869 +$45,118,057 $17.29 63
2024 Q1 16,171,755 $361,085,230 +$360,723,016 $22.33 54